| |
Method for early diagnosis and prognosis of Parkin |
Researchers at a German university have developed a simple test for determining the risk of being affected by Parkinson?s disease (PD), based on a DNA analysis of peripheral blood cells. It allows for a diagnosis of PD at a very early stage and may permit assessing a personīs risk of developing PD when becoming older, even if symptoms are not yet present. Biotech, pharmaceutical or healthcare companies are sought for commercial exploitation or further co-development. |
|
| |
Digital image for tissue and cell images |
A Finnish high-tech company has developed a technology that enables high-quality image analysis for cell and tissue analysis. Images can be sent to the company and customer will receive quantitative analysis results in less than two weeks. The results are documented in numerical form and as result images that can always be double-checked even after years of original analyses. The technology enables considerable cost savings. CROs and health care laboratories are sought.
|
|
| |
A new prognostic breast cancer biomarker |
A French academic research laboratory has patented a new predictive and prognostic breast cancer biomarker. This new tool will help doctors to choose the right treatment. Industrial partners for licence agreement are sought. |
|
| |
Device for diagnosis of neurological diseases |
The French company has developed a device for early disgnosis. This device can be used to diagnose several pathologies, such as Parkinson-plus syndromes and multiple sclerosis. Other pathologies are being studied. The French company is looking for partners to collaborate on different projects: cooperation on new diagnostic of neurological diseases, development of drugs, tests of new drugs. |
|
| |
Novel apoferritin nanoparticle for imaging |
A Finnish research group has developed a method to produce apoferritin nanoparticles consisting of globular protein gage with a hollow core. Targeting ligands are genetically fused on the particles. Targeting ligands are located in same positions (N-terminus) and thus the quality and the binding properties of the particles are homogenous. Invention can be applied in drug delivery, in vivo imaging, in vitro diagnostics and drug discovery. Partner is sought for developing commercial applications. |
|
